Related Experiment Video
Updated: Jun 18, 2026
03:22
Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
Published on: January 27, 2018
Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study
Bruce E Strober1, Kavita Menon, Amy McMichael
1Department of Dermatology, New York University Medical Center, 550 First Ave, TCH-158, New York, NY 10016, USA. strober@nyc.rr.com
Archives of Dermatology
|November 18, 2009
Summary
Alefacept did not show significant improvement for severe alopecia areata (AA) in a clinical trial. This T-cell inhibitor proved ineffective for treating this hair loss condition.
Area of Science:
- Dermatology
- Immunology
- Clinical Trials
Background:
- Alopecia areata (AA) is an autoimmune condition causing significant hair loss.
- Severe AA often presents challenges in treatment, with limited effective therapies.
- T-cell mediated autoimmune responses are implicated in the pathogenesis of AA.
Purpose of the Study:
- To evaluate the efficacy of alefacept in treating severe alopecia areata (AA).
- To determine if alefacept offers a therapeutic benefit for patients with chronic, treatment-resistant AA.
Main Methods:
- A multicenter, double-blind, randomized, placebo-controlled trial was conducted.
- Forty-five participants with severe AA (50%-95% scalp involvement) were enrolled.
- Alefacept was administered for 12 consecutive weeks, with outcomes assessed by the Severity of Alopecia Tool (SALT) score over 24 weeks.
Main Results:
- No statistically significant improvement in AA severity was observed in the alefacept group compared to placebo (P = .70).
- Alefacept did not demonstrate efficacy in improving scalp hair regrowth in this patient population.
Conclusions:
- Alefacept is ineffective for the treatment of severe alopecia areata.
- Further research into alternative therapeutic strategies for severe AA is warranted.
